U.S. Digital Therapeutics Market Size, Share, Growth, Trends, Company Analysis, Regional Insights and Forecast 2020 - 2027

The U.S. digital therapeutics market size is projected to reach USD 5.41 billion by 2027, expanding at a CAGR of 22% during the forecast period 2020 to 2027.

The U.S. digital therapeutics market size was valued at USD 1.01 billion in 2019, according to a new report by Vision Research Reports.

Technological advancement in healthcare IT, increasing demand for integrated healthcare system, and cost effective patient care are driving the market growth. The need for cost-effective healthcare is increasing due to rising healthcare expenditure. Digital health technology is being encouraged and preferred to avoid unnecessary costs and promote cheaper & alternative means of healthcare delivery, thus propelling the market. Moreover, rising demand for remote monitoring services due to increasing incidence of chronic diseases worldwide is one of the factors propelling market growth. Digital therapeutic applications allow patients to manage and treat diseases without constant medical intervention, thereby drastically reducing healthcare expenditure.

Increasing number of smartphone users in the U.S. is projected to drive market growth. The country has the highest smartphone and 4G adoption rates. Awareness regarding smart health tracking is also expected to increase due to rapidly rising smart healthcare devices. Digital therapeutics can offer on-demand care to patients, with the ability to diagnose and treat patients earlier. Moreover, biopharmaceutical companies are collaborating with digital therapeutic provides to give patients a better quality of care, thereby propelling the growth of the market.

Market Study

  • Diabetes dominated the application segment with a revenue share of over 22% in 2019. The growth can be attributed to increasing incidence of this diseases and demand for self-management and constant monitoring

  • CNS disease segment is expected to showcase the fastest CAGR over the forecast period owing to the increasing incidence of neurological diseases in the country.

  • Patients segment dominated the end-use segment with a share of around 31% in 2019 owing to increased adoption of healthcare IT services through Artificial Intelligence (AI) driven smartphone apps

  • Employer segment is expected to be the fastest-growing sub-segment over the forecast period. Employers are focusing on the management of employee healthcare costs, which is expected to drive segment growth.

  • In the wake of COVID 19 pandemic, patients with chronic diseases are facing challenges in managing medications, visiting healthcare providers, and maintaining a balanced diet. DTx therapy can be useful in managing patient conditions remotely

Some of the prominent players in the U.S. digital therapeutics market include:

  • Proteus Digital Health, Inc.

  • Omada Health, Inc.

  • Livongo Health, Inc.

  • 2Morrow, Inc.

  • Propeller Health

  • Fitbit, Inc.

  • Canary Health

  • Mango Health

  • WellDoc, Inc.

  • Noom, Inc.

  • Pear Therapeutics

  • Click Therapeutics, Inc.

  • Akili Interactive Labs, Inc.

Market Segmentation

Application Outlook

    • Diabetes

    • Obesity

    • CVD

    • Respiratory Diseases

    • Smoking Cessation

    • CNS Disease

    • Others

End-use Outlook

    • Patients

    • Providers

    • Payers

    • Employers

    • Others

Table Of Contents

Chapter 1 Methodology and Scope
                   1.1 Market Segmentation and Scope
                       1.1.1 Estimates and Forecast Timeline
                   1.2 Research Methodology
                   1.3 Information Procurement
                       1.3.1 Purchased database
                       1.3.2 GVR’s Internal Database
                       1.3.3 Secondary sources
                       1.3.4 Primary Research
                       1.3.5 Details of Primary Research
                           1.3.5.1 Data for primary interviews in the U.S.
                   1.4 Information or Data Analysis
                       1.4.1 Data Analysis Models
                   1.5 Market Formulation and Validation
                   1.6 Model Details
                       1.6.1 Commodity Flow Analysis (Model 1)
                   1.7 List of Secondary Sources
                   1.8 Report Objectives
Chapter 2 Executive Summary
                   2.1 Market Outlook
                       2.1.1 U.S. Digital Therapeutics market Outlook, 2016 - 2027 (USD Million)
                   2.2 U.S. Digital Therapeutics Market Summary, 2019
Chapter 3 Market Variables, Trends, and Scope
                   3.1 Market Lineage Outlook
                       3.1.1 Parent market analysis
                       3.1.2 Ancillary market Analysis
                   3.2 Penetration and Growth Prospect Mapping
                       3.2.1 Market driver analysis
                           3.2.1.1 Increasing smartphone penetration
                           3.2.1.2 Cost-effectiveness of digital health technology for providers and patients
                           3.2.1.3 Increasing demand for integrated healthcare systems and patient-centric care
                       3.2.2 Market restraint analysis
                           3.2.2.1 Reimbursement scenario
                   3.3 U.S. Digital Therapeutics Market Analysis Tools: Porters
                   3.4 PESTEL Analysis
Chapter 4 U.S. Digital Therapeutics Market: Competitive Analysis
                   4.1 Key Company Market Share Analysis, 2019 (Estimated)
                   4.2 Market Leaders
                   4.3 Innovators
                       4.3.1 Pear Therapeutics
                       4.3.2 Livongo Health
                       4.3.3 Omada Health, inc.
                       4.3.4 Propeller health
                   4.4 Major Deals & Strategic Alliances Analysis
Chapter 5 Impact of COVID-19
                   5.1 Current and Future Impact Analysis
                   5.2 Disease Prevalence Analysis (January to May 2020)
                   5.3 Impact on Mental Health
                   5.4 Impact on People with Chronic Diseases
                   5.5 Opportunity Analysis
                   5.6 List of private companies
Chapter 6 Application Estimates & Trend Analysis
                   6.1 Application Market Share Analysis, 2019 & 2027
                   6.2 Application Dashboard
                   6.3 Diabetes
                       6.3.1 Diabetes market estimates and forecasts, 2016 - 2027 (USD Million)
                   6.4 Obesity
                       6.4.1 Obesity market estimates and forecasts, 2016 - 2027 (USD Million)
                   6.5 Cardiovascular Diseases (CVD)
                       6.5.1 CVD market estimates and forecasts, 2016 - 2027 (USD Million)
                   6.6 CNS diseases
                       6.6.1 CNS diseases market estimates and forecasts, 2016 - 2027 (USD Million)
                   6.7 Respiratory Diseases
                       6.7.1 Respiratory diseases market estimates and forecasts, 2016 - 2027 (USD Million)
                   6.8 Smoking Cessation
                       6.8.1 Smoking Cessation market estimates and forecasts, 2016 - 2027 (USD Million)
                   6.9 Others
                       6.9.1 Others market estimates and forecasts, 2016 - 2027 (USD Million)
Chapter 7 End-use Estimates & Trend Analysis
                   7.1 End-use Market Share Analysis, 2019 & 2027
                   7.2 End-use Dashboard
                   7.3 Patients
                       7.3.1 Patients market estimates and forecasts, 2016 - 2027 (USD Million)
                   7.4 Providers
                       7.4.1 Providers market estimates and forecasts, 2016 - 2027 (USD Million)
                   7.5 Payers
                       7.5.1 PAYERS market estimates and forecasts, 2016 - 2027 (USD Million)
                   7.6 Employers
                       7.6.1 Employers market estimates and forecasts, 2016 - 2027 (USD Million)
                   7.7 Others
                       7.7.1 Others market estimates and forecasts, 2016 - 2027 (USD Million)
Chapter 8 Company Profiles
                   8.1 Proteus Digital Health, Inc.
                       8.1.1 Company overview
                       8.1.2 Financial performance
                       8.1.3 Product benchmarking
                       8.1.4 Strategic initiatives
                   8.2 Omada Health, Inc.
                       8.2.1 Company overview
                       8.2.2 Financial performance
                       8.2.3 Product benchmarking
                       8.2.4 Strategic initiatives
                   8.3 Livongo Health, Inc.
                       8.3.1 Company Overview
                       8.3.2 Financial Performance
                       8.3.3 Product Benchmarking
                       8.3.4 Strategic Initiatives
                   8.4 2Morrow, Inc.
                       8.4.1 Company Overview
                       8.4.2 Financial Performance
                       8.4.3 Product Benchmarking
                       8.4.4 STRATEGIC INITIATIVES
                   8.5 Propeller Health
                       8.5.1 Company Overview
                       8.5.2 Financial PERFORMANCE
                       8.5.3 Product Benchmarking
                       8.5.4 Strategic Initiatives
                   8.6 Fitbit, Inc. 
                       8.6.1 Company Overview
                       8.6.2 Financial Performance
                       8.6.3 Product Benchmarking
                       8.6.4 STRATEGIC INITIATIVES
                   8.7 Canary Health
                       8.7.1 Company Overview
                       8.7.2 Financial Performance
                       8.7.3 Product Benchmarking
                       8.7.4 Strategic Initiatives
                   8.8 Mango Health
                       8.8.1 Company Overview
                       8.8.2 Financial Performance
                       8.8.3 Product Benchmarking
                       8.8.4 STRATEGIC INITIATIVES
                   8.9 WellDoc, Inc.
                       8.9.1 Company Overview
                       8.9.2 Financial Performance
                       8.9.3 Product Benchmarking
                       8.9.4 Strategic Initiatives
                   8.10 Noom, Inc
                       8.10.1 Company Overview
                       8.10.2 Financial Performance
                       8.10.3 Product Benchmarking
                       8.10.4 STRATEGIC INITIATIVES
                   8.11 Pear Therapeutics
                       8.11.1 Company Overview
                       8.11.2 Financial Performance
                       8.11.3 Product Benchmarking
                       8.11.4 STRATEGIC INITIATIVES
                   8.12 Click Therapeutics, Inc.
                       8.12.1 Company overview
                       8.12.2 Financial performance
                       8.12.3 Product benchmarking
                       8.12.4 Strategic initiatives
                   8.13 Akili Interactive Labs, Inc.
                       8.13.1 Company overview
                       8.13.2 Financial performance
                       8.13.3 Product benchmarking
                       8.13.4 Strategic initiatives
                   8.14 Better Therapeutics, LLC
                       8.14.1 Company overview
                       8.14.2 Financial performance
                       8.14.3 Product benchmarking
                       8.14.4 Strategic initiatives

Proceed To Buy

USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask to Expert